J. Bagel, “Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial”, J of Skin, vol. 6, no. 6, p. s47, Nov. 2022.